Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer.

Cardiac function was evaluated in 86 breast cancer patients after standard chemotherapy, followed by ablative chemotherapy and chest irradiation. One patient died of subacute heart failure 3 months after ablative chemotherapy. At a minimum of 1 year's follow-up (range 1-11 years) left vertricul...

Descripción completa

Detalles Bibliográficos
Autores principales: de Graaf, H., Dolsma, W. V., Willemse, P. H., van der Graaf, W. T., Sleijfer, D. T., de Vries, E. G., Mulder, N. H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1997
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228075/
https://www.ncbi.nlm.nih.gov/pubmed/9328157
_version_ 1782149829740199936
author de Graaf, H.
Dolsma, W. V.
Willemse, P. H.
van der Graaf, W. T.
Sleijfer, D. T.
de Vries, E. G.
Mulder, N. H.
author_facet de Graaf, H.
Dolsma, W. V.
Willemse, P. H.
van der Graaf, W. T.
Sleijfer, D. T.
de Vries, E. G.
Mulder, N. H.
author_sort de Graaf, H.
collection PubMed
description Cardiac function was evaluated in 86 breast cancer patients after standard chemotherapy, followed by ablative chemotherapy and chest irradiation. One patient died of subacute heart failure 3 months after ablative chemotherapy. At a minimum of 1 year's follow-up (range 1-11 years) left vertricular ejection fraction (LVEF) was marginally abnormal in 4 of 27 disease-free survivors. One exceptional patient who received two transplantations is alive, with serious heart failure occurring after the second ablative chemotherapy. Including this patient, the percentage of patients free of clinical and subclinical cardiac dysfunction at 7 years is 78% (95% CI 61-95%). After ablative chemotherapy, cardiotoxicity was rarely life-threatening. The impact of subclinical cardiotoxicity in the long term is not clear and needs continued evaluation.
format Text
id pubmed-2228075
institution National Center for Biotechnology Information
language English
publishDate 1997
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22280752009-09-10 Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer. de Graaf, H. Dolsma, W. V. Willemse, P. H. van der Graaf, W. T. Sleijfer, D. T. de Vries, E. G. Mulder, N. H. Br J Cancer Research Article Cardiac function was evaluated in 86 breast cancer patients after standard chemotherapy, followed by ablative chemotherapy and chest irradiation. One patient died of subacute heart failure 3 months after ablative chemotherapy. At a minimum of 1 year's follow-up (range 1-11 years) left vertricular ejection fraction (LVEF) was marginally abnormal in 4 of 27 disease-free survivors. One exceptional patient who received two transplantations is alive, with serious heart failure occurring after the second ablative chemotherapy. Including this patient, the percentage of patients free of clinical and subclinical cardiac dysfunction at 7 years is 78% (95% CI 61-95%). After ablative chemotherapy, cardiotoxicity was rarely life-threatening. The impact of subclinical cardiotoxicity in the long term is not clear and needs continued evaluation. Nature Publishing Group 1997 /pmc/articles/PMC2228075/ /pubmed/9328157 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
de Graaf, H.
Dolsma, W. V.
Willemse, P. H.
van der Graaf, W. T.
Sleijfer, D. T.
de Vries, E. G.
Mulder, N. H.
Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer.
title Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer.
title_full Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer.
title_fullStr Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer.
title_full_unstemmed Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer.
title_short Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer.
title_sort cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228075/
https://www.ncbi.nlm.nih.gov/pubmed/9328157
work_keys_str_mv AT degraafh cardiotoxicityfromintensivechemotherapycombinedwithradiotherapyinbreastcancer
AT dolsmawv cardiotoxicityfromintensivechemotherapycombinedwithradiotherapyinbreastcancer
AT willemseph cardiotoxicityfromintensivechemotherapycombinedwithradiotherapyinbreastcancer
AT vandergraafwt cardiotoxicityfromintensivechemotherapycombinedwithradiotherapyinbreastcancer
AT sleijferdt cardiotoxicityfromintensivechemotherapycombinedwithradiotherapyinbreastcancer
AT devrieseg cardiotoxicityfromintensivechemotherapycombinedwithradiotherapyinbreastcancer
AT muldernh cardiotoxicityfromintensivechemotherapycombinedwithradiotherapyinbreastcancer

Ejemplares similares